WO2005037866A3 - Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose - Google Patents

Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose Download PDF

Info

Publication number
WO2005037866A3
WO2005037866A3 PCT/FR2004/002657 FR2004002657W WO2005037866A3 WO 2005037866 A3 WO2005037866 A3 WO 2005037866A3 FR 2004002657 W FR2004002657 W FR 2004002657W WO 2005037866 A3 WO2005037866 A3 WO 2005037866A3
Authority
WO
WIPO (PCT)
Prior art keywords
line
phagocytosis activity
igg3 anti
rhesus
anti rhesus
Prior art date
Application number
PCT/FR2004/002657
Other languages
English (en)
Other versions
WO2005037866A2 (fr
WO2005037866A8 (fr
Inventor
Romeuf Christophe De
Sylvie Jorieux
Dominique Bourel
Philippe Klein
Nicolas Bihoreau
Original Assignee
Lab Francais Du Fractionnement
Romeuf Christophe De
Sylvie Jorieux
Dominique Bourel
Philippe Klein
Nicolas Bihoreau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Romeuf Christophe De, Sylvie Jorieux, Dominique Bourel, Philippe Klein, Nicolas Bihoreau filed Critical Lab Francais Du Fractionnement
Priority to JP2006534803A priority Critical patent/JP2007533639A/ja
Priority to EP04817229A priority patent/EP1675616A2/fr
Priority to US10/575,218 priority patent/US20070218052A1/en
Priority to AU2004281220A priority patent/AU2004281220A1/en
Priority to CA002542508A priority patent/CA2542508A1/fr
Priority to BRPI0415420-7A priority patent/BRPI0415420A/pt
Publication of WO2005037866A2 publication Critical patent/WO2005037866A2/fr
Publication of WO2005037866A3 publication Critical patent/WO2005037866A3/fr
Priority to IL174949A priority patent/IL174949A0/en
Publication of WO2005037866A8 publication Critical patent/WO2005037866A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention se rapporte à des anticorps monoclonaux anti Rhesus D de classe IgG3 produits dans une lignée cellulaire de myélome de rat, la lignée YB2/0. Ces anticorps présentent une forte activité de phagocytose.
PCT/FR2004/002657 2003-10-16 2004-10-18 Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose WO2005037866A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2006534803A JP2007533639A (ja) 2003-10-16 2004-10-18 強い食作用活性を有するＹＢ２／０細胞株の抗ＲＨＥＳＵＳ−ＤＩｇＧ３
EP04817229A EP1675616A2 (fr) 2003-10-16 2004-10-18 Nouvelles igg3 utiles pour stimuler la phagocytose
US10/575,218 US20070218052A1 (en) 2003-10-16 2004-10-18 Novel lgG3 Antibodies for Stimulating Phagocytosis
AU2004281220A AU2004281220A1 (en) 2003-10-16 2004-10-18 IGG3 anti rhesus-D in the line YB2/0 having a high phagocytosis activity
CA002542508A CA2542508A1 (fr) 2003-10-16 2004-10-18 Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose
BRPI0415420-7A BRPI0415420A (pt) 2003-10-16 2004-10-18 igg3 úteis para estimular a fagocitose
IL174949A IL174949A0 (en) 2003-10-16 2006-04-11 ANTI RHESUS-D IgG3 IN A YB2/0 CELL LINE HAVING A STRONG PHAGOCYTOSIS ACTIVITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312087A FR2861078B1 (fr) 2003-10-16 2003-10-16 NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
FR0312087 2003-10-16

Publications (3)

Publication Number Publication Date
WO2005037866A2 WO2005037866A2 (fr) 2005-04-28
WO2005037866A3 true WO2005037866A3 (fr) 2005-07-21
WO2005037866A8 WO2005037866A8 (fr) 2006-06-01

Family

ID=34385205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/002657 WO2005037866A2 (fr) 2003-10-16 2004-10-18 Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose

Country Status (9)

Country Link
US (1) US20070218052A1 (fr)
EP (1) EP1675616A2 (fr)
JP (1) JP2007533639A (fr)
AU (1) AU2004281220A1 (fr)
BR (1) BRPI0415420A (fr)
CA (1) CA2542508A1 (fr)
FR (1) FR2861078B1 (fr)
IL (1) IL174949A0 (fr)
WO (1) WO2005037866A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053742A1 (fr) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653978A (en) * 1987-09-18 1997-08-05 The National Blood Authority Human anti-Rh(D) monoclonal antibodies and methods of use of antibodies in immunotherapy
WO2001077181A2 (fr) * 2000-04-12 2001-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps monoclonaux anti-rhesus d

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9305557A (pt) * 1992-06-26 1997-03-25 Aetsrn Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653978A (en) * 1987-09-18 1997-08-05 The National Blood Authority Human anti-Rh(D) monoclonal antibodies and methods of use of antibodies in immunotherapy
WO2001077181A2 (fr) * 2000-04-12 2001-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps monoclonaux anti-rhesus d

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREDIUS R G M ET AL: "ROLE OF NEUTROPHIL FCGRIIA (CD32) AND FCGRIIB (CD16) POLYMORPHIC FORMS IN PHAGOCYTOSIS OF HUMAN IGG1- AND IGG3-OPSONIZED BACTERIA AND ERYTHROCYTES", IMMUNOLOGY, OXFORD, GB, vol. 83, no. 4, 1994, pages 624 - 630, XP000914745, ISSN: 0019-2805 *
KLEIN P ET AL: "HUMAN RECOMBINANT ANTI-RH(D) MONOCLONAL ANTIBODIES: IMPROVEMENT OF BILOGICAL PROPERTIES BY IN VITRO CLASS-SWITCH", HUMAN ANTIBODIES, AMSTERDAM, NL, vol. 8, no. 1, 1997, pages 17 - 25, XP001015726, ISSN: 1093-2607 *
SCHARF O ET AL: "Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 14, July 2001 (2001-07-01), pages 6558 - 6565, XP002219983, ISSN: 0022-538X *
SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002965857, ISSN: 0021-9258 *
SHITARA KENYA ET AL: "A new vector for the high level expression of chimeric antibodies in myeloma cells", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 167, no. 1-2, 1994, pages 271 - 278, XP002911931, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
FR2861078A1 (fr) 2005-04-22
WO2005037866A2 (fr) 2005-04-28
FR2861078B1 (fr) 2007-09-21
US20070218052A1 (en) 2007-09-20
IL174949A0 (en) 2006-08-20
EP1675616A2 (fr) 2006-07-05
AU2004281220A1 (en) 2005-04-28
WO2005037866A8 (fr) 2006-06-01
CA2542508A1 (fr) 2005-04-28
JP2007533639A (ja) 2007-11-22
BRPI0415420A (pt) 2006-12-05

Similar Documents

Publication Publication Date Title
WO2006066568A3 (fr) Anticorps
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
WO2004029207A3 (fr) Variants fc optimises et methodes destinees a leur generation
WO2005092390A3 (fr) Conjugues d'amidon d'hydroxyalkyle et d'une proteine
WO2006096491A3 (fr) Compositions d'anticorps anti-ctla-4
WO2003062375A3 (fr) Stabilisation de polypeptides exposes à l'uree
EP2216046A3 (fr) Anticorps anti-glypican 3
WO2007120334A3 (fr) Méthodes et compositions de ciblage de la polyubiquitine
WO2007147122A3 (fr) Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine
WO2007008943A3 (fr) Proteines optimisees qui ciblent la molecule ep-cam
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
WO2006014683A3 (fr) Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
WO2003100033A3 (fr) Anticorps anti-$g(a)v$g(b)6
WO2008079995A3 (fr) Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps
WO2006071856A3 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
WO2007110678A3 (fr) Anticorps neutralisants et procédés d'utilisation
AU2003259718A1 (en) Methods for humanizing rabbit monoclonal antibodies
WO2006028936A3 (fr) Molecules heteromultimeriques
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2007044616A3 (fr) Anticorps anti-cd30 optimises
WO2007002222A3 (fr) Conjugues anticorps psma-medicament
WO2005080432A3 (fr) Anticorps a regions hypervariables reparees
WO2004085478A3 (fr) Proteines hybrides fc ameliorees
WO2001098358A3 (fr) Compositions permettant d'identifier et d'isoler des cellules embryonnaires
WO2008043145A8 (fr) Hybridomes produisant des anticorps dirigés contre le récepteur p2x7 non fonctionnel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 174949

Country of ref document: IL

Ref document number: 2004817229

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2542508

Country of ref document: CA

Ref document number: 2004281220

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006534803

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004281220

Country of ref document: AU

Date of ref document: 20041018

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004281220

Country of ref document: AU

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE IN ENGLISH REPLACED BY CORRECT TITLE AND UNDER (57) PUBLISHED ABSTRACT IN ENGLISH REPLACED BY CORRECT ABSTRACT

WWP Wipo information: published in national office

Ref document number: 2004817229

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0415420

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007218052

Country of ref document: US

Ref document number: 10575218

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10575218

Country of ref document: US